Cardiorenal Protection in Diabetic Kidney Disease

Autor: Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney

Publikováno v: Endocrinology and Metabolism, Vol 36, Iss 2, Pp 256-269 (2021)

Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic cont

Externí odkaz: https://doaj.org/article/dcdef2be7f3f470bbc1be5e22dbefee0

SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series

Autor: Marko Škrtić, David Z. I. Cherney, Vikas S. Sridhar, Christopher T. M. Chan, Abhijat Kitchlu

Publikováno v: Canadian Journal of Kidney Health and Disease, Vol 8 (2021)

Background: Nephrectomy is the mainstay of treatment for many kidney cancers, but has been correlated with increased incidence of acute kidney injury (AKI) and chronic kidney disease (CKD). Recently, sodium-glucose cotransporter-2 (SGLT2) inhibition

Externí odkaz: https://doaj.org/article/5df261a382d845ebb54c6afa425308e5

SGLT2 Inhibitors: The Sweet Success for Kidneys

Autor: Atit Dharia, Abid Khan, Vikas S. Sridhar, David Z.I. Cherney

Publikováno v: Annual Review of Medicine. 74:369-384

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV outcomes in patients with type 2 diabetes mellitus (T2D). Secondary analy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::306f1fd4e372c826a7f587753fa8b9dc
https://doi.org/10.1146/annurev-med-042921-102135

The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3

Autor: Vikas S. Sridhar, Hiddo J.L. Heerspink, Michael J. Davies, Phillip Banks, Manon Girard, Satish K. Garg, David Z.I. Cherney

Publikováno v: Diabetes Care.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::711764959a9802a1b7d60c86db20eb1a
https://doi.org/10.2337/dc23-0129

Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis

Autor: Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M.J. Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson

Publikováno v: Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5, pp. 14791641221130043 . https://doi.org/10.1177/14791641221130043
Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5 . https://doi.org/10.1177/14791641221130043

Background The indication for treatment of type 1 diabetes(T1D) with the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1362b97ba69086d2c89615b716f65782
https://pubmed.ncbi.nlm.nih.gov/36262089